Prelude Therapeutics Incorporated : Q3 2022 Corporate Presentation

Precision Oncology

Redefined

Q3 2022

Forward-Looking Statements

This presentation contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: our plans to develop and commercialize small molecule therapies, our expectations about timing and ability to commence, enroll or complete clinical studies and to obtain regulatory approvals for PRT543, PRT811, PRT1419, PRT2527, PRT3645 and other candidates in development, the ability of our product candidates to treat various cancers, the ability to discover additional suitable candidates for regulatory approval, the potential impact of the COVID-19 pandemic and the sufficiency of our cash and cash equivalents to fund our operations.

Any statements contained herein or provided orally that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by such terminology as ''believe,'' ''may,'' ''will,'' ''potentially,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''could,'' ''would,'' ''project,'' ''plan,'' ''expect'' and similar expressions that convey uncertainty of future events or outcomes, although not all forward-looking statements contain these words. Statements, including forward-looking statements, speak only to the date they are provided (unless an earlier date is indicated).

These forward-looking statements are based on the beliefs of our management as well as assumptions made by and information currently available to us. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. If such assumptions do not fully materialize or prove incorrect, the events or circumstances referred to in the forward-looking statements may not occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations, except as required by law. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Additional risks and uncertainties that could affect our business are included under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for the three months ended June 30, 2022 and in our Annual Report on Form 10-K for the year ended December 31, 2021.

2

Prelude Therapeutics: Vision

Build a fully integrated oncology company on the foundation of drug discovery excellence to deliver novel precision cancer medicines to underserved patients

3

Prelude Therapeutics: Key Reasons to Invest

Internal	Effective	Strong
Discovery	R&D
Execution
Engine	Approach
Scientists with	Seamless	Proprietary
proven track	integration	diversified
records	between biology	pipeline
	and chemistry

Focused

Clinical

Development

Driving to 'go/ no go' decisions

with a sense of

urgency

Well

Capitalized

~$246M cash

• marketable securities (6/30/22)

4

Experienced Management Team: Proven Track Records

Founding member

Jane Huang M.D.	Laurent Chardonnet
Chief Financial Officer
President and Chief
Medical Officer

Kris Vaddi, PhD

Founder &

Chief Executive Officer

Andrew Combs, PhD	Peggy Scherle, PhD
Executive Vice President	Chief Scientific Officer
and Head of Chemistry

Board of Directors

Paul Friedman, MD

CEO

Former CEO

Mardi Dier

CFO

Former CFO,

CBO

Victor Sandor, MD

Former CMO

David Bonita, MD

General Partner

Julian C. Baker

Managing Member

Baker Brothers Investments

Kris Vaddi, PhD

Founder &

Chief Executive Officer

Martin Babler

Former CEO

5